Position in ACAD
as of Jun 30, 2026
· filed Jul 28, 2026
Position Value
$1,978,460
+$237,728 QoQ
Shares Held
78,200
0.0% QoQ
Ownership
0.046%
of shares outstanding
% of Portfolio
0.06%
of 13F equity value
Holder Rank
#3
of 67 holders
Holding Since
Mar 2024
10 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ACAD Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026WESBANCO BANK INC holds $21,116,746 across 14 Biotechnology names. ACAD ranks #5 (9.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | EXEL |
Exelixis, Inc.
|
55,034 | $2,994,399 | |
| 2 | AXSM |
Axsome Therapeutics, Inc.
|
8,800 | $2,153,976 | |
| 3 | ARQT |
Arcutis Biotherapeutics, Inc.
|
81,100 | $2,126,442 | |
| 4 | VKTX |
Viking Therapeutics, Inc.
|
52,000 | $2,028,520 | |
| 5 | ACAD |
Acadia Pharmaceuticals Inc
This page
|
78,200 | $1,978,460 | |
| 6 | CGON |
CG Oncology, Inc.
|
22,300 | $1,584,415 | |
| 7 | NRIX |
Nurix Therapeutics, Inc.
|
62,700 | $1,521,102 | |
| 8 | IDYA |
IDEAYA Biosciences, Inc.
|
39,700 | $1,479,619 |
All Filings in ACAD
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,978,460 | 78,200 | Shares | Other | 2026-07-28 | |
| 2026-03-31 | $1,740,732 | 78,200 | Shares | Other | 2026-04-21 | |
| 2025-12-31 | $2,088,722 | 78,200 | Shares | Other | 2026-02-03 | |
| 2025-09-30 | $1,668,788 | 78,200 | Shares | Other | 2025-11-06 | |
| 2025-06-30 | $1,686,774 | 78,200 | Shares | Other | 2025-07-07 | |
| 2025-03-31 | $860,398 | 51,800 | Shares | Other | 2025-04-14 | |
| 2024-12-31 | $950,530 | 51,800 | Shares | Other | 2025-01-17 | |
| 2024-09-30 | $796,684 | 51,800 | Shares | Other | 2024-10-11 | |
| 2024-06-30 | $841,750 | 51,800 | Shares | Other | 2024-07-11 | |
| 2024-03-31 | $495,532 | 26,800 | Shares | Other | 2024-04-23 | |
| No filing history on record for this holder in this stock. | ||||||